The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
You guys are all thinking about stuff that you already know. We’re trying to pull in new investors as well and this webpage is a great summary of the situation and the potential. Nothing new, sure, but simplifying the research process for new investors is a nice little move.
Like that. Clears up a few things that many have decided to argue about on here.
Livinhope - for future reference just divide valuation by number of shares.
I’m with you on this one long run. Can’t see any reason why they wouldn’t need to jump through the same hoops.
Totally agree. AVCT pre covid mcap circa £50m.
“... because people are getting out on the small rise as they have lost faith, and there are 1-2 more Antibody gold standard tests that keep the market informed, and has the potential.“
You don’t even seem to recognise that GDR and ODX do different things.
Will be interesting to see what happens in US this afternoon.
Agree. Just checking you didn’t know something I didn’t. Thanks for detailed reply.
Lp - of course you could be right, but how do you know??
But I can’t see which one. Any ideas?
It’s teabiscuit.
Presumably going down the robotics route will allow them to reduce the cost of production, increase capacity, and fundamentally become very attractive to the huge Indian market
Is the highest in the world (excluding countries with populations less than 10m), so the gov / NHS must be doing something right.
Perfect, thanks tech. Was waiting for you to appear and give me the answer!
2 buys to 1 sell at the moment
What are molecular tests? Are they antigen? Assume so...
If not, why has the FDA only EUA’d 2 antigen tests??
Some products work very hard to get in the shelves of big supermarkets...just because they don’t try to sell to corner shops does that make them a failure??
GDR have made it very clear who their target audience is, they just need to wait for approvals. We know they’re not in the habit of random AVCT style RNS’s, so why do you seem to expect them? Nothing has changed.
Teabiscuit. I appreciate what you’re saying, but what makes you believe that these new products from competitors won’t have to go through exactly the same process...possibly even longer with further increase in applications as time progresses?
Completely agree longrun. People on here act like their sat there twiddling thumbs waiting for the phone to ring from the FDA. They will be flat out working on sales and production. Don’t forget, this is a massive opportunity for the company and the employees there as well, they will be busting a gut to make it count regardless of whether the tell you what their doing every week or not.
Faith in the product and the demand, that’s the key.